Compare QTRX & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | QTRX | HURA |
|---|---|---|
| Founded | 2007 | 2009 |
| Country | United States | United States |
| Employees | N/A | 22 |
| Industry | Biotechnology: Laboratory Analytical Instruments | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.0M | 141.4M |
| IPO Year | 2017 | N/A |
| Metric | QTRX | HURA |
|---|---|---|
| Price | $3.33 | $2.52 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $6.00 | ★ $9.50 |
| AVG Volume (30 Days) | ★ 1.0M | 453.3K |
| Earning Date | 05-06-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $37,632,000.00 | N/A |
| Revenue This Year | $25.49 | N/A |
| Revenue Next Year | $10.04 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 64.52 | N/A |
| 52 Week Low | $2.40 | $0.41 |
| 52 Week High | $8.77 | $3.90 |
| Indicator | QTRX | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 55.09 | 60.17 |
| Support Level | $3.11 | $2.38 |
| Resistance Level | $3.81 | $2.68 |
| Average True Range (ATR) | 0.34 | 0.18 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 40.44 | 99.89 |
Quanterix Corp is a life sciences company accelerating biomarker breakthroughs from discovery to diagnostics using ultra-sensitive translational research and spatial biology instruments, consumables, and services. The company sells proprietary instruments and related consumables to research laboratories, contract research organizations (CROs), academic institutions, and bio-pharmaceutical companies, and provides contract research services and clinical laboratory testing services, including four Laboratory Developed Tests (LDTs), through its Accelerator Laboratory. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, and SP-X Imaging and Analysis System. Geographically, it operates in North America, EMEA, and the Asia Pacific.
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.